Citius Oncology Partners with EVERSANA for LYMPHIR Commercialization

jueves, 16 de octubre de 2025, 8:51 am ET1 min de lectura
CTOR--

Citius Oncology has signed an exclusive commercialization agreement with EVERSANA to support the planned Q4 2025 launch of LYMPHIR, a therapy for relapsed or refractory cutaneous T-cell lymphoma. EVERSANA will provide integrated commercialization services, including medical information, pharmacovigilance, revenue cycle management, and data and analytics, to enhance launch readiness and market entry for LYMPHIR. This agreement marks a transformative milestone for Citius Oncology, allowing it to extend its commercial capabilities and strengthen its operational readiness for the launch of LYMPHIR.

Citius Oncology Partners with EVERSANA for LYMPHIR Commercialization

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios